Q3 2011 · —
Revenue$202.19M$202.19M +8.3% vs Q3 2010+4.6% vs Q2 2011
Net Income$11.24M$11.24M −31.8% vs Q3 2010+1,508.4% vs Q2 2011
EPS Diluted$0.39$0.39 −29.1% vs Q3 2010+1,850.0% vs Q2 2011
Gross Profit$123,534,000+5.2%
Operating Income$18,291,000−33.0%
Operating Cash Flowderived$23,795,000−19.7%
Free Cash Flowderived$11,552,000−48.5%
Margins · derived
Gross margin61.1%−1.8 pt vs Q3 2010
Operating margin9.0%−5.6 pt vs Q3 2010
Net margin5.6%−3.3 pt vs Q3 2010
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2011 | Q3 2010 | Q3 2009 |
|---|---|---|---|
| Revenue | $202.19M | $186.64M | $172.29M |
| Net Income | $11.24M | $16.48M | $14.43M |
| EPS Diluted | $0.39 | $0.55 | $0.49 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR